ANN ARBOR, Mich. - ENDRA Life Sciences Inc. (NASDAQ: NASDAQ:NDRA), the developer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has expanded its intellectual property portfolio with the addition of five new patents. This growth brings the company's total to 80 issued patents worldwide, a significant benchmark for the Michigan-based firm.
The newly issued patents include three European patents and two from the Chinese National Intellectual Property Administration. These patents cover innovations in radio frequency applicator devices, methods for determining material types and parameters using TAEUS technology, and systems for monitoring tissue temperature during surgical procedures.
Francois Michelon, Chairman and CEO of ENDRA, commented on the expansion of the IP portfolio, highlighting the company's efforts to secure its technology in key global markets and exploring licensing opportunities beyond their core focus. The pursuit of licensing suggests potential growth avenues for ENDRA.
The European patents (EP4051151, EP4037554, and EP4037551) relate to the RF applicator and systems for determining material types and parameters, potentially extending the applications of TAEUS beyond liver fat quantification and outside human body measurements. The Chinese patents (ZL2019800868227 and ZL202110813939X) focus on methods for monitoring tissue temperature during energy-based surgical procedures like thermotherapy and cryotherapy.
ENDRA Life Sciences is recognized for pioneering TAEUS, a technology aimed at characterizing tissue in a manner similar to MRI but at a fraction of the cost and more conveniently at the point of patient care. The company's initial focus is on measuring liver fat to assess and monitor Steatotic Liver Disease, a condition affecting over two billion people globally.
The information in this article is based on a press release statement from ENDRA Life Sciences Inc.
InvestingPro Insights
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has achieved a milestone in expanding its intellectual property with new patents, indicating its commitment to innovation and securing its market position. However, a deeper look into the company's financial health through InvestingPro metrics provides a nuanced picture of its current standing.
With a market capitalization of just $3.2 million, ENDRA is categorized among the smaller players in the medical device sector. The company's P/E ratio stands at -0.18, reflecting that it is not generating positive earnings at present. This is further substantiated by an adjusted P/E ratio of -0.32 for the last twelve months as of Q4 2023, which suggests that investors are wary of the company's ability to turn a profit in the near term.
Moreover, ENDRA's price has experienced significant volatility. The one-week price total return shows an impressive gain of 18.56%, yet this is set against a backdrop of a one-year price total return of -83.09%, highlighting a steep decline over a longer period. This volatility is critical for potential investors to consider, as it underscores both the risks and opportunities inherent in investing in ENDRA.
InvestingPro Tips reveal that ENDRA holds more cash than debt, which is a positive sign of financial stability. Nonetheless, the company is also quickly burning through cash, which raises concerns about its long-term sustainability. Additionally, while the stock has seen a significant return over the last week, analysts do not anticipate the company will be profitable this year, and the stock has fared poorly over the last month.
For investors interested in a more comprehensive analysis, there are additional InvestingPro Tips available. These insights can help investors make more informed decisions, especially when considering the company's recent advancements in intellectual property against its financial metrics. For access to these tips, visit https://www.investing.com/pro/NDRA and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.